Literature DB >> 10652595

Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity.

C Miret1, J Font, R Molina, M Garcia-Carrasco, X Filella, M Ramos, R Cervera, A Ballesta, M Ingelmo.   

Abstract

OBJECTIVE: Bcl-2 translocation or overexpression is found in many types of malignancy, possibly through alteration of the apoptosis mechanism. It has also been suggested that similar apoptotic alterations may be important in the pathogenesis of systemic lupus erythematosus (SLE). It is believed that a process of apoptosis at the stage of maturation or differentiation of lymphocytes may be related to the beginning of an autoimmune event, due to the non-elimination of autoreactive lymphocytes. The aim of this study is to test bcl-2 antigen expression in human SLE peripheral blood and to analyze its relationship with disease activity.
MATERIALS AND METHODS: Serum levels of bcl-2 were studied by enzyme-linked immunoabsorbent assay in whole blood samples in 68 patients with SLE and its correlation with disease activity according to SLE disease activity index (SLEDAI).
RESULTS: No significant differences were found in bcl-2 levels between all SLE patients and controls. We observed increased levels of bcl-2 in active SLE patients in relation to inactive (p = 0.0003) and controls (p = 0.02). Our results show a significant correlation between bcl-2 levels and SLEDAI values (R = 0.46, P < 0.001).
CONCLUSIONS: These results suggest that bcl-2 levels are related to disease activity and that this protein may play a role in the pathogenesis of SLE.

Entities:  

Mesh:

Year:  1999        PMID: 10652595

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression.

Authors:  C Lutz; M Mozaffari; V Tosevski; M Caj; P Cippà; B L McRae; C L Graff; G Rogler; M Fried; M Hausmann
Journal:  Clin Exp Immunol       Date:  2015-05-19       Impact factor: 4.330

2.  Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus.

Authors:  Tianfu Wu; Xiangmei Qin; Zoran Kurepa; Kirthi Raman Kumar; Kui Liu; Hasna Kanta; Xin J Zhou; Anne B Satterthwaite; Laurie S Davis; Chandra Mohan
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.

Authors:  Mukul Minocha; Jiewei Zeng; Jeroen K Medema; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.